Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2022 11:00 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary...
September 26, 2022 08:00 ET | Source: LAVA Therapeutics N.V.; Seagen Inc.

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors – – LAVA to...
September 13, 2022 16:05 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Initial Phase 1/2a clinical findings for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients demonstrated encouraging anti-tumor activity and safety profile; on track...
September 07, 2022 07:41 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary...
June 16, 2022 16:05 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

UTRECHT, The Netherlands and PHILADELPHIA, June 16, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary...
June 15, 2022 07:00 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics Announces Two Appointments to its Board of Directors

UTRECHT, The Netherlands and PHILADELPHIA, June 15, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary...
June 02, 2022 07:00 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, June 02, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary...
June 01, 2022 07:00 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary...
May 31, 2022 16:05 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics Announces Annual Meeting of Shareholders

UTRECHT, The Netherlands and PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical stage immuno-oncology company focused on developing its...
May 17, 2022 07:00 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

LAVA-051 updated interim clinical data from Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 ASCO Annual...